Table 2 Model projections of annual clinical outcomes at baseline and with different timing and coverage

 Influenza symptomatic cases without antiviral treatment²

2,301,185 (1044395–4,135,596)

2,902,800 (1347273–5,246,107)

162,568 (52024–391,760)

460,854 (149728–1,046,816)

 Influenza symptomatic cases at baseline^2,3

2,231,561 (1004289–4,046,681)

2,805,437 (1293191–5,117,997)

154,932 (49132–379,116)

441,098 (141980–1,016,914)

 Treating early⁴ while keeping baseline treatment coverage²

65,201 (36977–84,458)

2.9 (2.1–3.7)

90,847 (49702–121,703)

3.2 (2.4–3.8)

7012 (2599–11,923)

4.5 (3.1–5.3)

18,229 (6990–28,306)

4.1 (2.8–4.9)

 Treating 20% of infected individuals² early⁴

116,833 (65688–152,635)

5.2 (3.8–6.5)

160,451 (87138–216,869)

5.7 (4.2–6.7)

12,543 (4611–21,568)

8.1 (5.7–9.4)

32,561 (12372–51,130)

7.4 (5.0–8.7)

 Hospitalizations without antiviral treatment ²

9896 (4365–18,385)

13,998 (6298–26,222)

902 (208–2261)

2297 (723–5546)

 Hospitalizations at baseline^2,3

9301 (4069–17,431)

13,110 (5860–24,783)

833 (256–2119)

2130 (665–5123)

 Treating early⁴ while keeping baseline treatment coverage²

513 (253–822)

5.5 (4.7–6.2)

764 (374–1243)

5.8 (5.0–6.4)

59 (20–123)

7.1 (5.8–7.8)

143 (49–279)

6.7 (5.4–7.4)

 Treating 20% of infected individuals² early⁴

1021 (494–1686)

11.0 (9.7–12.1)

1506 (725–2522)

11.5 (10.2–12.4)

115 (38–247)

13.8 (11.7–14.9)

279 (95–564)

13.1 (11.0–14.2)